samedi 10 octobre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 9, 2026

Precision Medicine Analysis Report 2026: A $237.28 Billion Market by 2031 - Strategic Pharma-Big-Tech Alliances Speeding Precision Drug Discovery

View original at globenewswire.com
Precision Medicine Analysis Report 2026: A $237.28 Billion Market by 2031 - Strategic Pharma-Big-Tech Alliances Speeding Precision Drug Discovery Dublin, Feb…
Opening lines of the source · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Asia-Pacific is the fastest-growing region with a 14.12% CAGR

    80% confidence
  • More than 15 FDA clearances since 2024 have tied targeted drugs to specific biomarker tests, widening the addressable patient pool for precision oncology

    80% confidence
  • Next-generation sequencing captured 33.78% of the precision medicine market share in 2025

    80% confidence
  • Guardant Health's Shield blood test detects colorectal cancer with 83% sensitivity in average-risk adults

    80% confidence
  • North America led the precision medicine market with a 47.85% revenue share in 2025

    80% confidence
  • SomaLogic measures 10,000 proteins from a microliter sample, producing high-density data that AI models translate into early disease risk scores

    80% confidence
  • The Precision Medicine market size in 2026 is estimated at USD 125.71 billion, growing from 2025 value of USD 110.68 billion with 2031 projections showing USD 237.28 billion, growing at 13.58% CAGR over 2026-2031

    80% confidence
  • China's Human Genome Project 2 plans to sequence 80 million genomes, creating the world's largest reference panel for variant interpretation

    80% confidence
  • Artificial intelligence and machine learning is the fastest-growing segment at a 17.62% CAGR

    80% confidence
  • Japan has committed to analyze 100,000 cancer genomes under a national program to guide targeted therapy development

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Notre lecture des données ›
Signaux que nous suivons
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Tendances que nous surveillons ›
Là où les sources divergent
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,986
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,986 faits vérifiés avec la source5,365 documents sources archivés
Interrogez ces données → isubstrate.com